The Cancer Protocol Review Committee's (CPRC) mission is to evaluate, approve or reject, monitor, and re-review on an annual basis all University of Minnesota clinical cancer research protocols.

• When evaluating the scientific merit of a cancer research protocol, the scientific relevance, validity of the hypothesis, adequate study design, biostatistical input, adequate patient population, and feasibility of timely completion are considered.
• When evaluating the priority of the proposed study in regards to competing protocols, scientific merit, impact on existing studies, patient availability, and Cancer Center resources are considered.

Primary and secondary protocol reviewers are designated to review each protocol. In addition, a biostatistician reviews the protocol for biostatistical methodology. At a subsequent CPRC meeting, the reviewers critique the protocol and make the recommendation for approval, approval with stipulations, deferment, or disapproval. The committee discusses the protocol and then votes on the motion.

Protocols are reviewed annually by progress reports that indicate the accrual rate and progress toward study endpoints. Protocols determined to have inadequate accrual, to be without scientific progress, or have little likelihood of completion may be terminated based on committee vote.

• CPRC submission deadlines and committee meeting schedules (MSWord doc)
• CPRC/Therapeutic Interventional (CPRC/TI) Review and Monitoring
• Classifications of Protocols Reviewed by the CPRC/Non-Therapeutic Interventional (CPRC/NTI)
• Interaction with the Institutional Review Board